The field of high dose rate (HDR) brachytherapy has witnessed rapid advances in optimisation techniques that aim to balance the dual imperatives of maximising tumour dose while minimising exposure to ...
Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective This review highlights strategies to integrate ...
Please provide your email address to receive an email when new articles are posted on . Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile ...
The medical community today faces a deceptively simple question: How quickly should we act when a child’s life is on the line? I’m a pediatric oncologist, so my answer won’t surprise you — I think we ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs) ...
Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback